ConductScience.org, home

Paper ยท 21889194

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE and 23 others. Cell, 2011. Cited by 2,411 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Papers, record 21889194. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21889194

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
PubMed
Journal
Cell
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2,411
iCite
Relative citation ratio, by iCite
52.2
iCite
Revised in PubMed
2025-05-29
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Delmore JEJake E
2Issa GCGhayas C
3Lemieux MEMadeleine E
4Rahl PBPeter B
5Shi JJunwei
6Jacobs HMHannah M
7Kastritis EEfstathios
8Gilpatrick TTimothy
9Paranal RMRonald M
10Qi JJun

1 to 10 of 24Source PubMed

See all 24 authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Drug DiscoveryMajor topic
Multiple MyelomaMajor topic
Proto-Oncogene Proteins c-mycMajor topic
Animals
Azepines
Benzodiazepines
Cell Line, Tumor
Disease Models, Animal
Humans
Mice
Nuclear Proteins
Protein Structure, Tertiary
Transcriptional Activation
Triazoles

Source PubMed

Grants11

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01CA46455NCI NIH HHSUnited StatesPubMedPubMed
R01 CA136671NCI NIH HHSUnited StatesR01CA136671PubMed and NIHNIH RePORTER
R01 AG020686NIA NIH HHSUnited StatesR01AG020686PubMed and NIHNIH RePORTER
R01 CA050947NCI NIH HHSUnited StatesR01CA050947PubMed and NIHNIH RePORTER
K08CA128972NCI NIH HHSUnited StatesK08CA128972PubMed and NIHNIH RePORTER
R01 CA133966NCI NIH HHSUnited StatesR01CA133966PubMed and NIHNIH RePORTER
Wellcome TrustUnited KingdomPubMedPubMed
R01CA050947NCI NIH HHSUnited StatesR01CA050947PubMed and NIHNIH RePORTER
R01HG002668NHGRI NIH HHSUnited StatesR01HG002668PubMed and NIHNIH RePORTER
K08 CA128972NCI NIH HHSUnited StatesK08CA128972PubMed and NIHNIH RePORTER

1 to 10 of 11

See all 11 grants

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in21,941,280Targeting MYC? You BET.https://conductscience.org/library/papers/21941280PubMed
Comment in21,959,283Targeting MYC? You BET.https://conductscience.org/library/papers/21959283PubMed

References63

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117,664,422Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17664422PubMed
23,011,271Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development.Cell1986https://conductscience.org/library/papers/3011271PubMed
317,690,245Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17690245PubMed
48,425,220Oncogenic activity of the c-Myc protein requires dimerization with Max.Cell1993https://conductscience.org/library/papers/8425220PubMed
519,549,893Evaluation of the 8q24 prostate cancer risk locus and MYC expression.Cancer Res2009https://conductscience.org/library/papers/19549893PubMed
611,823,794Sibling rivalry in the E2F family.Nat Rev Mol Cell Biol2002https://conductscience.org/library/papers/11823794PubMed
76,413,865Transcriptional activation of immunoglobulin alpha heavy-chain genes by translocation of the c-myc oncogene.Nature1983https://conductscience.org/library/papers/6413865PubMed
819,861,459MYC-induced cancer cell energy metabolism and therapeutic opportunities.Clin Cancer Res2009https://conductscience.org/library/papers/19861459PubMed
912,200,383A molecular compendium of genes expressed in multiple myeloma.Blood2002https://conductscience.org/library/papers/12200383PubMed
1015,902,208An inhibitor of Bcl-2 family proteins induces regression of solid tumours.Nature2005https://conductscience.org/library/papers/15902208PubMed

Cited by1,766

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,411 citations.

PMIDTitleJournalYearIn PapersSource
42,959,345Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states.Front Med (Lausanne)2026https://conductscience.org/library/papers/42959345PubMed
42,950,026FOSL1-associated condensates modulate superenhancer-mediated selected IL-1 family gene activation in psoriasis.Sci Adv2026https://conductscience.org/library/papers/42950026PubMed
42,888,198BUB signaling in cancer and molecular insights into targeted therapies.Commun Biol2026https://conductscience.org/library/papers/42888198PubMed
42,875,775RAS pathway mutations orchestrate chromatin reconfiguration and transcriptional rewiring in colorectal cancer.Cell Commun Signal2026https://conductscience.org/library/papers/42875775PubMed
42,840,296Protein arginine methylation in transcription and epigenetic regulation.Front Epigenet Epigenom2023https://conductscience.org/library/papers/42840296PubMed
42,798,998Fragment-Based Discovery of BRD4-BD2 Selective Binders: Biophysical Validation and Structural Insights for Domain-Selective Inhibitor Design.ACS Omega2026https://conductscience.org/library/papers/42798998PubMed
42,778,564Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.Nat Commun2026https://conductscience.org/library/papers/42778564PubMed
42,603,101Epigenetic reprogramming of lineage switching in cancer.FEBS Lett2026https://conductscience.org/library/papers/42603101PubMed
42,558,596Cell competition within breast tumor microenvironment: emerging role of cancer stem cells and immune cells in tumor progression and therapeutic implications.Front Oncol2026https://conductscience.org/library/papers/42558596PubMed
42,512,290Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy.Cancers (Basel)2026https://conductscience.org/library/papers/42512290PubMed

1 to 10 of 1,766

See all 1,766 cited by

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
GEOGSE31365

Source GEO

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21889194

GET https://conductscience.org/api/papers/v1/21889194/authors?page=2